Gyala Therapeutics — Series A · €540K partial: only one investor's ticket was disclosed

CDTI Innovación announced, via its Innvierte programme, that it is entering the capital of Gyala Therapeutics alongside NARA Health Capital and founding investor Invivo Ventures; CDTI's committed ticket is €540,000 and the total round size was not disclosed. Gyala is a Hospital Clínic-IDIBAPS spin-off developing GYA01, a first-in-class CD84-targeting CAR-T therapy, and the money funds a Phase I trial in relapsed/refractory acute myeloid leukaemia.